Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Xoma以2200万美元的预付款从DaréBioscience手中收购了三项女性健康资产的经济权益
- Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023.
- XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women's health assets: Ovaprene, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder.
- Bayer HealthCare holds the exclusive rights to U.S. commercialization of Ovaprene.
- XOMA provided $22 million upfront as non-dilutive royalty capital solution to Daré Bioscience.
- 全球女性医疗保健公司Organon于2023年第四季度启动了XACIATO的商业活动。
- XOMA进一步扩大了其后期产品组合，通过合成特许权使用费和另外两项女性健康资产的里程碑式权益：Ovaprene，一种潜在的3期无激素月用阴道内避孕药Ovaprene和西地那非乳膏，占3.6％，是女性性唤起障碍的潜在第三阶段候选药物。
- 拜耳医疗拥有Ovaprene在美国商业化的专有权。
- XOMA向达瑞生物科学提供了2200万澳元的预付特许权使用费资本解决方案，作为非稀释性特许权使用费资本解决方案。